Immunodesigners synthesizes diastereomeric prodrug for hepatitis B
Aug. 1, 2024
Immunodesigners Co. Ltd. has discovered optical isomers of 2'-fluoro-6'-methylene carbocyclic adenosine monophosphate prodrug reported to be useful for the treatment of chronic hepatitis B.